Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
381 stopped studies mapped to Malignant Kidney Neoplasm and descendants · 86% state a reason
Over the 381 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05471401 | GI Organ Tracking Via Balloon Applicators | N/A | withdrawn | Jul 22, 2022 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT02542202 | Stereotactic Body Radiation Therapy in Treating Patients With Metastatic or Recurrent… | N/A | terminated | Sep 4, 2015 | University of Chicago | due to slow enrollment | Enrollment / accrual |
| NCT03562507 | Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic…(ERICA) | Phase 2 | terminated | Jun 19, 2018 | University of Michigan Rogel Cancer Center | Lack of patient population | Other (stated, no rule matched) |
| NCT03140176 | Real-world Clinical Patterns Of Care And Outcomes Among AfME mRCC Patients Receiving…(OPTIMISE) | — | terminated | May 4, 2017 | Pfizer | The study was terminated early due to the inability to recruit the planned number of patients | Enrollment / accrual |
| NCT04429321 | Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell… | Phase 1 | terminated | Jun 12, 2020 | Abramson Cancer Center at Penn Medicine | failure to accrue | Enrollment / accrual |
| NCT06377722 | Cabozantinib Treatment Prior to Cytoreductive Nephrectomy in Patients With Advanced or… | Phase 2 | terminated | Apr 22, 2024 | Fundacion Oncosur | The achieved number of samples has been smaller than the planned 50 thus, a mainly descriptive… | Other (stated, no rule matched) |
| NCT03311334 | A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in… | Phase 1 / Phase 2 | terminated | Oct 17, 2017 | Sumitomo Pharma America, Inc. | Sponsor's decision to terminate development of the program. | Sponsor / business decision |
| NCT05061537 | Study of PF-07263689 in Participants With Selected Advanced Solid Tumors | Phase 1 | terminated | Sep 29, 2021 | Pfizer | The study was terminated by the Sponsor due to business decision and not due to any safety concerns… | Safety / toxicity |
| NCT04714983 | DNX-2440 for Resectable Colorectal Liver Metastasis | Phase 1 | suspended | Jan 20, 2021 | DNAtrix, Inc. | DNAtrix management decision not based on study design, safety, or site performance. | Safety / toxicity |
| NCT04691375 | A Study of PY314 in Subjects With Advanced Solid Tumors | Phase 1 | terminated | Dec 31, 2020 | Ikena Oncology | Sponsor business decision. | Sponsor / business decision |
| NCT02782715 | Microwave Ablation With MRI-Guided SBRT Boost in Renal Cell Carcinoma | Phase 1 / Phase 2 | terminated | May 25, 2016 | University of Wisconsin, Madison | slow accrual | Enrollment / accrual |
| NCT05121948 | A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2… | Phase 1 | terminated | Nov 16, 2021 | HiberCell, Inc. | sponsor decision | Sponsor / business decision |
| NCT03709771 | Novel Mechanisms and Predictors of VEGF Receptor Inhibitor- or Immune Checkpoint… | — | terminated | Oct 17, 2018 | Vanderbilt University Medical Center | Study terminated due to unmet targeted accrual goals with only 2 subjects accrued out of 80 planned… | COVID-19 / pandemic |
| NCT04187872 | LITT and Pembrolizumab in Recurrent Brain Metastasis(TORCH) | Phase 1 | terminated | Dec 5, 2019 | University of Florida | Sponsor terminated | Other (stated, no rule matched) |
| NCT04341740 | Investigating Marrow Infiltrating Lymphocytes in Renal Cell Carcinoma(WindMIL-001) | N/A | terminated | Apr 10, 2020 | University of Oklahoma | Study funding was withdrawn. | Funding |
| NCT04555603 | Axitinib Therapy Management Study | — | withdrawn | Sep 18, 2020 | Pfizer | Failed at data quality assurance process before any analyses would be performed | Other (stated, no rule matched) |
| NCT02232646 | A Study of BBI503 in Adult Patients With Advanced Urologic Malignancies | Phase 2 | withdrawn | Sep 5, 2014 | Sumitomo Pharma America, Inc. | Low feasibility | Other (stated, no rule matched) |
| NCT04300140 | Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or… | Phase 1 / Phase 2 | terminated | Mar 9, 2020 | Aravive, Inc. | Due to business reasons | Sponsor / business decision |
| NCT00496756 | Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer | Phase 2 | terminated | Jul 4, 2007 | University of Nebraska | Low accrual rate | Enrollment / accrual |
| NCT03824808 | Effect of Perioperative Intravenous Lidocaine Infusion in Robotic-Assisted Urologic… | Phase 4 | terminated | Jan 31, 2019 | University of Missouri-Columbia | Challenges with recruitment of surgical research subjects in the target population. | Enrollment / accrual |
| NCT06090318 | Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With… | Phase 1 / Phase 2 | withdrawn | Oct 19, 2023 | Rain Oncology Inc | Sponsor Decision | Sponsor / business decision |
| NCT03623490 | Optimizing the Management of Patients With Oral Therapy(IPAC) | N/A | terminated | Aug 9, 2018 | Centre Georges Francois Leclerc | Following an insufficient recruitment, the sponsor decided to halt prematurely inclusions | Enrollment / accrual |
| NCT00014131 | Vaccine Therapy in Treating Patients With Kidney Cancer | Phase 1 | terminated | Jan 27, 2003 | Lisata Therapeutics, Inc. | change in corporate priorities | Other (stated, no rule matched) |
| NCT04203901 | Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma | Phase 2 | terminated | Dec 18, 2019 | CoImmune | Strategic corporate decision | Sponsor / business decision |
| NCT04106167 | Long-term, Non-interventional, Observational Study Following Treatment With Fate… | — | terminated | Sep 26, 2019 | Fate Therapeutics | This study was terminated by the Sponsor. | Other (stated, no rule matched) |
| NCT05176288 | Avelumab, Palbociclib and Axitinib in Advanced RCC(APART) | Phase 2 | withdrawn | Jan 4, 2022 | Bradley A. McGregor, MD | The overall protocol will be changed in a new amendment, which will be resubmitted under the new… | Other (stated, no rule matched) |
| NCT04271254 | PET/MR Characterization of Renal Cell Carcinomas | N/A | terminated | Feb 17, 2020 | UNC Lineberger Comprehensive Cancer Center | Funding insufficiency. | Funding |
| NCT00489710 | Talabostat in Treating Patients With Metastatic Kidney Cancer | Phase 2 | withdrawn | Jun 21, 2007 | University of Nebraska | safety reasons | Safety / toxicity |
| NCT04398368 | Gemcitabine for the Prevention of Intravesical Recurrence of Urothelial Cancer in… | Phase 2 | terminated | May 21, 2020 | Mayo Clinic | Focus research efforts on other projects. | Other (stated, no rule matched) |
| NCT03024996 | A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma…(IMmotion010) | Phase 3 | terminated | Jan 19, 2017 | Hoffmann-La Roche | The sponsor decided to terminate this study before the protocol-defined end-of-study, as permitted… | Sponsor / business decision |
| NCT03576131 | GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors | Phase 1 / Phase 2 | terminated | Jul 3, 2018 | Genmab | Sponsor decision | Sponsor / business decision |
| NCT00788125 | Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With… | Phase 1 / Phase 2 | terminated | Nov 10, 2008 | City of Hope Medical Center | Terminated early due a shift in resources after lackluster performance of the drug. | Other (stated, no rule matched) |
| NCT03397394 | Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma(ATLAS) | Phase 2 | terminated | Jan 12, 2018 | pharmaand GmbH | Efficacy did not meet the continuance criteria and DMC recommended to stop enrollment. | Efficacy / futility |
| NCT03637803 | Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors | Phase 1 / Phase 2 | terminated | Aug 20, 2018 | 4D pharma plc | Sponsor insolvency | Other (stated, no rule matched) |
| NCT04603365 | Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell… | Phase 2 | withdrawn | Oct 26, 2020 | Jonsson Comprehensive Cancer Center | enrollment | Enrollment / accrual |
| NCT03729245 | A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared… | Phase 3 | terminated | Nov 2, 2018 | Nektar Therapeutics | Sponsor decision | Sponsor / business decision |
| NCT02771626 | Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal… | Phase 1 / Phase 2 | terminated | May 13, 2016 | Calithera Biosciences, Inc | lack of efficacy | Efficacy / futility |
| NCT03435640 | REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With…(REVEAL) | Phase 1 / Phase 2 | terminated | Feb 19, 2018 | Nektar Therapeutics | Based on the overall results from the Phase 1 part of the study the sponsor decided to end the… | Safety / toxicity |
| NCT02654340 | Biomarkers for Tuberous Sclerosis Complex (BioTuScCom)(TuScCom) | — | terminated | Jan 13, 2016 | CENTOGENE GmbH Rostock | Study no longer pursued. | Other (stated, no rule matched) |
| NCT03671304 | Mobile Intervention - Physical Activity in Cancer Treatment | N/A | terminated | Sep 14, 2018 | University of Texas Southwestern Medical Center | The study was prematurely discontinued, the application utilized with the fitbit is no longer being… | Other (stated, no rule matched) |
| NCT04088500 | A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced… | Phase 2 | terminated | Sep 12, 2019 | Bristol-Myers Squibb | Slow accrual | Enrollment / accrual |
| NCT02923531 | Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma | Phase 1 / Phase 2 | terminated | Oct 4, 2016 | X4 Pharmaceuticals | Due to low enrollment, the study was terminated early. | Enrollment / accrual |
| NCT04147143 | CaboCHECK - Cabozantinib in Adult Patients With Advanced Renal Cell Carcinoma Following… | — | terminated | Oct 31, 2019 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Due to insufficient recruitment rate, recruitmend has been terminated after inclusion of 56 patients | Enrollment / accrual |
| NCT04941365 | Quantifying Systemic Immunosuppression to Personalize Cancer Therapy(SERPENTINE) | N/A | withdrawn | Jun 28, 2021 | Institut du Cancer de Montpellier - Val d'Aurelle | please refer to NCT05621837 | Other (stated, no rule matched) |
| NCT03387514 | Functional Microscale Organotypic Assays to Predict Patient Response to Anti-Angiogenesis…(UW17104) | Phase 2 | terminated | Jan 2, 2018 | University of Wisconsin, Madison | Termination of funding due to low subject enrollment due to change in standard of care systemic… | Enrollment / accrual |
| NCT00520533 | Study of Safety and Functional Imaging of cG250 and Sunitinib in Patients With Advanced… | Phase 1 | terminated | Aug 24, 2007 | Ludwig Institute for Cancer Research | Closed prematurely due to toxicity | Safety / toxicity |
| NCT01727336 | Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma | Phase 2 | terminated | Nov 16, 2012 | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | The study was terminated by the sponsor following unblinding of the Progression Free Survival… | Other (stated, no rule matched) |
| NCT04127318 | Low-moderate Intensity Pedaling During Immunotherapy Administration | N/A | withdrawn | Oct 15, 2019 | Rush University Medical Center | lack of resources | Other (stated, no rule matched) |
| NCT04060342 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With… | Phase 1 | terminated | Aug 19, 2019 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | No clear benefit of GB1275 was observed either as monotherapy or in combination with pembrolizumab. | Other (stated, no rule matched) |
| NCT01582009 | Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal… | Phase 1 / Phase 2 | terminated | Apr 20, 2012 | Roswell Park Cancer Institute | pts off study, PI left institute | Investigator |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jun 13, 2024source: clinicaltrials